...
首页> 外文期刊>International Urology and Nephrology >Use of diagnostic categories in urinary cytology in comparison with the bladder tumour antigen (BTA) test in bladder cancer patients.
【24h】

Use of diagnostic categories in urinary cytology in comparison with the bladder tumour antigen (BTA) test in bladder cancer patients.

机译:与膀胱癌患者的膀胱肿瘤抗原(BTA)测试相比,在尿液细胞学中使用诊断类别。

获取原文
获取原文并翻译 | 示例
           

摘要

In recent years the use of diagnostic categories for extragenital cytology has increasingly been discussed as an approach to improve the quality of reports. Diagnostic categories reflect the adequacy of the materials for interpretation and the presence or absence of cancer cells. There is a tendency to add intermediate groups as qualifying probably malignant cases or findings associated with a serious cancer risk. Since 1971 we have added one of the following to the final diagnosis in all cases: unsatisfactory for cytological diagnosis, negative for cancer, repeat test suggested, suspicious of cancer, and positive for cancer. To evaluate whether diagnostic categories are useful for comparison of cytological results with those of an alternative test, cytological data were compared with the results of the Bard bladder tumour antigen (BTA) test in voided urine from 119 patients (76 with and 43 without bladder cancer). The diagnostic categories enabled us to calculate sensitivities and specificities of cytology based on different thresholds or decision levels. The BTA test had significantly higher sensitivity (79%) and lower specificity (60%) than urinary cytology with three different thresholds in cytology results (sensitivities: 16-43%, specificities: 81-100%). The present findings suggest that diagnostic categories improve comparison of cytologic results with those of alternative screening and diagnostic aids such as the BTA test.
机译:近年来,越来越多地讨论将诊断类别用于生殖器外细胞学,作为提高报告质量的一种方法。诊断类别反映了用于解释的材料是否足够以及癌细胞的存在与否。有增加中间组作为可能的恶性病例或与严重癌症风险相关的发现的趋势。自1971年以来,我们在所有病例的最终诊断中增加了以下一项:对细胞学诊断不满意,对癌症阴性,建议重复试验,对癌症可疑以及对癌症阳性。为了评估诊断类别是否可用于比较细胞学结果与替代测试的细胞学结果,将细胞学数据与119例患者(76例和43例无膀胱癌的患者)排尿时的Bard膀胱肿瘤抗原(BTA)测试结果进行了比较)。诊断类别使我们能够根据不同的阈值或决策水平来计算细胞学的敏感性和特异性。与尿液细胞学相比,BTA测试具有显着更高的敏感性(79%)和更低的特异性(60%),并且在细胞学结果中具有三个不同的阈值(敏感性:16-43%,特异性:81-100%)。目前的发现表明,诊断类别可以改善细胞学结果与其他筛选和诊断辅助手段(例如BTA测试)的比较。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号